Scotiabank Initiates Coverage on Blueprint Medicines (NASDAQ:BPMC)
Scotiabank started coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report issued on Friday, Marketbeat Ratings reports. The firm issued a sector outperform rating and a $150.00 price target on the biotechnology company’s stock. Several other equities analysts have also recently issued reports on BPMC. JPMorgan Chase & Co. boosted their […]
Scotiabank started coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report issued on Friday, Marketbeat Ratings reports. The firm issued a sector outperform rating and a $150.00 price target on the biotechnology company’s stock. Several other equities analysts have also recently issued reports on BPMC. JPMorgan Chase & Co. boosted their […]
